{"id":"NCT00440297","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Hepatitis B Vaccine Predialysis/Dialysis Study (V232-060)","officialTitle":"A Study in Renal Predialysis and Dialysis Patients of the Safety, Tolerability, and Immunogenicity of Recombinant Hepatitis B Vaccine Manufactured With a Modified Process","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-12","primaryCompletion":"2008-05","completion":"2008-05","firstPosted":"2007-02-27","resultsPosted":"2009-07-08","lastUpdate":"2017-04-13"},"enrollment":277,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Hepatitis B Virus Infection"],"interventions":[{"type":"BIOLOGICAL","name":"Comparator: modified process hepatitis B vaccine","otherNames":[]},{"type":"BIOLOGICAL","name":"Comparator: ENGERIX-B™","otherNames":[]}],"arms":[{"label":"Modified process hepatitis B vaccine","type":"EXPERIMENTAL"},{"label":"ENGERIX-B™2","type":"ACTIVE_COMPARATOR"}],"summary":"To describe the immunogenicity and safety of modified process hepatitis B vaccine administered to renal predialysis and dialysis patients","primaryOutcome":{"measure":"The Number of Seroprotected Participants to the Modified Process Hepatitis B Vaccine and ENGERIX-B™ (Currently Licensed Vaccine) at Month 7","timeFrame":"7 months (1 month after the third dose)","effectByArm":[{"arm":"Modified Process Hepatitis B Vaccine","deltaMin":49,"sd":null},{"arm":"ENGERIX-B™","deltaMin":64,"sd":null}],"pValues":[{"comp":"OG000","p":null},{"comp":"OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":7},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["25252192"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":11},"commonTop":["Injection site Pain","Injection site Erythema","Injection site Swelling","Headache","Diarrhea"]}}